Media resources

Contact Info

Julissa Viana

Vice President, Corporate Communications and Investor Relations

About Verastem

RAS pathway-driven cancers—such as low-grade serous ovarian cancer and KRAS-mutant non-small cell lung cancer—are difficult to treat. For patients with these forms of cancer, currently available treatments face resistance mechanisms and aren’t effective and often have side effects that make them difficult to tolerate. This means patients quickly run out of therapeutic options. At Verastem Oncology, we’re committed to ensuring options exist. For more information about the work we’re doing at Verastem Oncology, please access our Resources section or contact Julissa Viana via email at

story icon 2
Ovarian cancer has long been a challenge to treat, as the disease is often diagnosed late due to its varied progression patterns and symptoms that can be hard to recognize initially. However, needed clarity came when the disease was recognized not as a single entity, but as different cancers with distinct biological and molecular characteristics, leading to the separation of low-grade serous ovarian cancer (LGSOC) from its high-grade counterpart
Story Icon 1
It is a remarkable time for biopharmaceutical research targeting oncogenic RAS mutations that, for decades, have been considered undruggable. A sophisticated collaborative effort across industry and academia is under way to meet the epic complexities of the RAS signaling pathway. This week I have the honor of moderating four sessions at the  Digital RAS-Targeted Drug Discovery summit  (Feb 23-25) . This forum is an opportunity for preclinical and
Story Icon 3
Over the past year, those of us working in pharmaceutical oncology R&D have watched with awe as industry colleagues worked together to speed vaccinations for COVID-19 from the lab to patients’ arms in record time. Breakthroughs in cancer research, typically don’t happen that quickly. In fact, chemotherapy remains a standard of care for many cancers that have few effective and safe treatment choices. For example, despite advances in ovarian cancer